So when Pfizer invests in these projects, it is naturally more important than those outside investors.

What they have to do now is to make this industrial investment combination model in the country!

What the Ninth Laboratory needs to do now is to replicate the set that Pfizer did in the United States.

If this set is done, it will not only be a matter of making money, but the most important thing is to enhance the company's position in the industry.

For example, Pfizer, you should know that this company has a huge influence in beautiful countries.

It can even be said that no matter where they go, they have their own halo.

People who are not in the pharmaceutical industry may not know that the representatives of this company are the targets of others chasing stars no matter where they go in the industry.

Why is this happening?

In fact, it is because they have done a good job in the integration of industry investment.

Not only do they develop various new drugs themselves, but they also bring a group of younger brothers to make money while making money on their own.

People are famously charitable in the circle. As long as your company is creative and passes their evaluation, you can get money from them.

And the prices and conditions are very reasonable.

This is much easier than finding venture capital to get money.

Many pharmaceutical companies actually have a headache when they start, that is, how can they obtain sufficient initial start-up capital.

Although in a beautiful country, there are many various angel funds, and venture capitalists.

But unlike those companies that engage in the Internet, those companies can easily get initial funds from venture capitalists.

However, it is difficult for those engaged in pharmaceutical research and development to obtain funds because they have too high risk of failure in research and development, and venture capital investors are not willing to invest money for them.

Moreover, the R&D cycle is long, and it is very likely that you will have to invest money in it for a long time, so ordinary investors are not willing to invest in such R&D companies.

In addition, even if there are those who are willing to invest, the requirements will be very strict, and they will always require very high shares, or they will be assigned to the R&D team to mess around.

If there is anything more, they will directly ask to take away the results of the research and development.

Therefore, many people engaged in pharmaceutical research and development do not like to deal with investors like venture capital and Angel Fund because in their opinion, these investors are robbers and liars.

On the other hand, large companies like Pfizer are much more kind in their opinion.

After all, first of all, are you all the peers? The hardships of developing dogs? Everyone understands.

Secondly, Pfizer knows better the value of the projects they develop, so the requirements will not be too excessive.

Because of this? Every year when Pfizer holds a pharmaceutical expo, there are countless small and medium-sized pharmaceutical companies across the United States and even around the world, and even research groups in universities, sign up for it.

Because this is a very good platform for everyone to show off.

Here? If your creativity and projects can attract Pfizer's attention and get their investment, you are not far from success.

Even if you cannot get the favor of Pfizer here, you have the opportunity to get the attention of other pharmaceutical companies.

Even if you can't get investment from other pharmaceutical companies? At least you have the opportunity to reach some unique investors.

You should know that in this industry, there are always a few investors with unique vision.

If you can get their attention and investment, you can also get the initial starting capital.

This is the main reason why Pfizer has this status today.

What the Ninth Laboratory and Xiao Feng need to do now is to learn and apply Pfizer's strategy in China.

You should know that in China, the field of original medicines has always been very backward.

In the past few decades, they were mainly catching up. At that time, the main purpose of major pharmaceutical factories across the country was to enable domestic people to have medicinal use.

In the past twenty years, the basic medication needs of domestic residents have been met.

But many domestic pharmaceutical factories are backed by the big market? They can easily have a meal? Therefore, the pursuit of original drugs is not that great.

After all, the investment required for original drugs is too large? The cycle is long, the investment is high, and the results are slow. No boss is willing to do such a project.

Therefore, there are many high-end drug markets in China, which are basically monopolized by large pharmaceutical factories in Europe, America and Japan.

Recently, the country has also noticed this issue, so it is also encouraging domestic pharmaceutical factories to start the route of R&D and innovation.

So in recent times, major domestic pharmaceutical factories have also increased their research on this aspect.

In domestic medical universities, there are still many projects and projects, all following the international trends and looking for the latest and most suitable R&D routes.

There are even many small businesses in China that have emerged like bamboo shoots after the rain. With Internet thinking, they are also engaged in research and development.

In fact, these small and medium-sized enterprises and the research teams in universities are very worthy of investment, and they do need funds in urgent need.

But I have never had a suitable channel to get funds.

For example, the research teams in domestic medical universities mainly rely on the funding of the school.

To be honest, the school's funding is really limited for the dozens of project teams waiting to be fed.

Every year, everyone can get a little bit of it, which is good enough to ensure that they don’t starve to death.

As for those small and medium-sized enterprises, the same is true. People in the company are obviously very creative, but in the process of R&D, a large amount of capital investment is required.

And even if the data in the laboratory are successful, these small businesses will be blinded by the next step when live clinical trials are to be conducted.

Even if they can afford the early costs, the cost in later live clinical trials is too high.

Domestic clinical trials will take five years to complete, and the data collection will basically start with thousands.

Such consumption can be afforded by the large pharmaceutical factories in China, except for those of the largest pharmaceutical factories.

For small and medium-sized pharmaceutical companies, their work is basically over at this point.

After all, they can't afford to go overseas to conduct clinical trials, although it's very cheap to conduct clinical trials in India and Africa.

But they don’t have that kind of resources and are not familiar with the place, so they can’t afford to invest.

So when it comes to this point, the first choice of these pharmaceutical companies is to sell their research results.

Moreover, their first choice is to sell it to foreign large factories, because these foreign large factories will indeed offer a good price.

Although these large foreign pharmaceutical factories spent some money to get these results, the little money they paid was just a drop in the bucket compared to what they got.

Because these small and medium-sized pharmaceutical R&D companies in China have completed the most difficult early stage of a project, from creativity to later stage laboratory experiments, and the collection of laboratory data has been completed.

In the end, all they have to do is complete the clinical trial, and this step is nothing to them.

Once the last step is completed, you can apply for a new drug to be launched. At that time, this drug can bring them hundreds of billions of benefits in the global market.

This is really not an exaggeration at all!

And looking back, they will also support their local media, saying that the people of H have no sense of innovation...

Anyway, such a fucking thing is not a secret that cannot be told in the medical circle.

However, Xiao Feng didn't know about this when he was not in the industry before, but after understanding it, he always feels sorry and distressed for those domestic companies.

There is no way, who told us that we had no conditions to reach out to pull them!

But now, their ninth laboratory is finally capable.

Moreover, there are so many wealthy capital in China and bigwigs. In fact, many of these people are willing to invest in the pharmaceutical industry.

After all, the aging in China is already very serious now, and everyone knows that the big health industry will definitely have great potential in the future.

However, the entry threshold for the pharmaceutical field is not low. Not only do you need to be rich, but the most important thing is that you also need to have enough understanding of the pharmaceutical field.

Knowing that business can be done, that business is a completely liar, so you can avoid being deceived.

Because of this, those big guys and capital are very cautious about investing in small and medium-sized pharmaceutical companies.

What the Ninth Laboratory needs to do is to integrate the resources on both sides and then connect them.

Xiao Feng means to build a large exhibition hall in the sports new city section that is about to begin construction.

We can usually undertake various exhibitions. Every year when it is fixed, the ninth laboratory can also come forward to hold large-scale medical fairs and medical device fairs across the country.

With the current status of the Ninth Laboratory in the domestic pharmaceutical industry, they have come to the forefront that the large domestic pharmaceutical factories and hospitals really have to give face.

And I believe they will definitely like it. There is such a platform that allows them to have the opportunity to connect with pharmaceutical companies and hospitals all over the country.

At the same time, they will also give pharmaceutical companies across the country that develop original drugs or pharmaceutical companies that develop medical devices.

Let them show their creativity on this platform. If their creativity is recognized by the Ninth Laboratory, then they can get investment from the Quanye Fund.

In addition, their platform can also help other capital and bigwigs who are interested in investing in pharmaceutical companies to find the targets they think are suitable here.

Anyway, Xiao Feng’s original intention is to make money for everyone.

As long as the industry-investment combination is done well, domestic pharmaceutical research and development will embark on the road of prosperity in the future.

And their Ninth Laboratory and Quanye Fund can use this to establish their position in the domestic medical field in one fell swoop.

Nowadays, the field of medicine in China can be said to be an era when many heroes emerge.

Old state-owned enterprises are still growing stronger, and many new generations of private pharmaceutical companies are also emerging.
Chapter completed!